Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century.

conditional survival relative survival surgery treatment uro-oncology

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
16 May 2023
Historique:
received: 08 03 2023
revised: 10 04 2023
accepted: 10 05 2023
medline: 22 6 2023
pubmed: 22 6 2023
entrez: 22 6 2023
Statut: epublish

Résumé

Kidney and bladder cancers share etiology and relatively good recent survival, but long-term studies are rare. We analyzed survival for these cancers in Denmark, Finland, Norway (NO), and Sweden (SE) over a 50-year period (1971-2020). Relative 1- and 5-year survival data were obtained from the NORDCAN database, and we additionally calculated conditional 5/1-year survival. In 2016-2020, 5-year survivals for male kidney (79.0%) and bladder (81.6%) cancers were best in SE. For female kidney cancer, NO survival reached 80.0%, and for bladder cancer, SE survival reached 76.1%. The magnitude of 5-year survival improvements during the 50-year period in kidney cancer was over 40% units; for bladder cancer, the improvement was over 20% units. Survival in bladder cancer was worse for women than for men, particularly in year 1. In both cancers, deaths in the first year were approximately as many as in the subsequent 4 years. We could document an impressive development for kidney cancer with tripled male and doubled female 5-year survival in 50 years. Additionally, for bladder cancer, a steady improvement was recorded. The current challenges are to curb early mortality and target treatment to reduce long-term mortality.

Identifiants

pubmed: 37345119
pii: cancers15102782
doi: 10.3390/cancers15102782
pmc: PMC10216153
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : the European Union's Horizon 2020 research and innovation programme
ID : grant No 856620 (Chaperon)
Organisme : The Swedish Research Council, Jane and Aatos Erkko Foundation, Sigrid Juselius Foundation, Finnish Cancer Organizations, University of Helsinki, Helsinki University Central Hospital, Novo Nordisk Foundation, Päivikki and Sakari Sohlberg Foundation, Finnis
ID : ID Project No. LX22NPO5102

Références

JHEP Rep. 2022 Sep 29;4(12):100602
pubmed: 36352895
PLoS One. 2021 Jun 22;16(6):e0253236
pubmed: 34157049
Scand J Urol. 2022 Jun;56(3):227-232
pubmed: 35389306
Acta Oncol. 2010 Jun;49(5):725-36
pubmed: 20491528
Acta Oncol. 2001;40(2-3):371-90
pubmed: 11441942
J Urol. 2016 Apr;195(4 Pt 1):872-9
pubmed: 26523878
BJU Int. 2014 Feb;113(2):228-35
pubmed: 23890347
Biomed Res Int. 2015;2015:456040
pubmed: 26539495
Gut. 2018 Jul;67(7):1306-1316
pubmed: 28754778
PLoS One. 2022 Jan 4;17(1):e0261124
pubmed: 34982793
Acta Oncol. 2020 Nov;59(11):1266-1274
pubmed: 33073632
Eur Urol Open Sci. 2020 Nov 28;22:61-73
pubmed: 34337479
Cancers (Basel). 2023 Feb 03;15(3):
pubmed: 36765946
Health Policy. 2012 Apr;105(1):65-70
pubmed: 22136810
Cancer. 2010 Nov 15;116(22):5235-42
pubmed: 20665490
Acta Oncol. 2022 Jan;61(1):58-63
pubmed: 34807805
Cancers (Basel). 2021 Aug 30;13(17):
pubmed: 34503195
Scand J Urol Nephrol Suppl. 1991;138:179-85
pubmed: 1785001
Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):193-199
pubmed: 31615790
Ann Oncol. 2012 Mar;23(3):760-764
pubmed: 21821544
BMC Cancer. 2021 May 25;21(1):604
pubmed: 34034676
Eur Urol. 2020 Dec;78(6):893-906
pubmed: 32972792
World J Urol. 2018 Sep;36(9):1341-1353
pubmed: 29610964
Urol Oncol. 2019 Dec;37(12):853-861
pubmed: 31481299
Scand J Urol. 2014 Jun;48(3):231-8
pubmed: 24666102
J Urol. 2019 May;201(5):893-901
pubmed: 30676477
World J Oncol. 2020 Jun;11(3):79-87
pubmed: 32494314
Br J Cancer. 1996 Jul;74(1):123-7
pubmed: 8679445
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Eur Urol. 2018 Jan;73(1):111-122
pubmed: 28867446
Nature. 2014 Jan 16;505(7483):302-8
pubmed: 24429628
Contemp Oncol (Pozn). 2013;17(2):123-7
pubmed: 23788977
Eur J Cancer. 2022 Nov;175:77-85
pubmed: 36096040
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
Ann Oncol. 2022 Mar;33(3):244-258
pubmed: 34861372
Scand J Urol. 2019 Aug;53(4):193-199
pubmed: 31262208
PLoS One. 2022 May 27;17(5):e0268922
pubmed: 35622857
Scand J Urol. 2016;50(1):14-20
pubmed: 26382667
Ann Oncol. 2021 Dec;32(12):1511-1519
pubmed: 34597799
Eur J Cancer. 2022 Sep;172:76-84
pubmed: 35759813

Auteurs

Filip Tichanek (F)

Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 30605 Pilsen, Czech Republic.
Institute of Pathological Physiology, Faculty of Medicine in Pilsen, Charles University, 32300 Pilsen, Czech Republic.

Asta Försti (A)

Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.

Akseli Hemminki (A)

Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, 00290 Helsinki, Finland.
Comprehensive Cancer Center, Helsinki University Hospital, 00290 Helsinki, Finland.

Otto Hemminki (O)

Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, 00290 Helsinki, Finland.
Department of Urology, Helsinki University Hospital, 00290 Helsinki, Finland.

Kari Hemminki (K)

Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 30605 Pilsen, Czech Republic.
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany.

Classifications MeSH